Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05446298 · ClinicalTrials.gov registry record · Phase 2
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by OncoC4.
- Active
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT05446298: Active Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by OncoC4.
NCT05446298 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by OncoC4. The registered enrollment target is 58 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05446298, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by OncoC4.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Primary Outcome
To assess the efficacy of ONC-392 and pembrolizumab combination therapy in objective response rate per RECIST1.1.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ONC-392
Study Locations (20)
Texas
- Texas Oncology, P. A. - Austin, USOR. 417 - Austin
- Texas Oncology, P.A., Fort Worth - USOR. 420 - Fort Worth
- Texas Oncology, P. A. Woodlands - USOR, 418 - The Woodlands
- Texas Oncology - Northeast Texas - USOR, 423 - Tyler
Arizona
- Cancer Treatment Centers of America, Phoenix. 403 - Goodyear
- Honor Health, USOR, 406 - Phoenix
Illinois
- Sudarshan Sharma, MD. LTD. 414 - Hinsdale
- Cancer Treatment Centers of America, Chicago. 410 - Zion
Kentucky
- Baptist Health Lexington, 407 - Lexington
- Norton Cancer Institute - St. Matthews, 416 - Louisville
Connecticut
- Nuvance Health System, 401 - Danbury
Florida
- Baptist MD Anderson Cancer Center, 404 - Jacksonville
Indiana
- Northwest Cancer Centers - Dyer, IN - USOR, 422 - Dyer
Louisiana
- Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409 - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT05446298 still lists
NCT05446298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05446298 names 20 study sites across 14 states, led by Texas, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT05446298 about?
NCT05446298 is a clinical study titled "ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer". This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
What is the current status of trial NCT05446298?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2022-12-22. Estimated completion is 2026-06-30.
What conditions does trial NCT05446298 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma of Ovary.
What interventions are being tested in trial NCT05446298?
The interventions under investigation include: Pembrolizumab (DRUG), ONC-392 (DRUG).
Who is sponsoring clinical trial NCT05446298?
This trial is sponsored by OncoC4, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05446298 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05446298's enrollment target sits among peer trials
58 201st of 322 higher than 121 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI